Use of a hormone-sensitive (LNCaP) and a hormone-resistant (LNCaP-r) cell line in prostate cancer research.
BACKGROUND
In order to develop a hormone-resistant analog to the hormone sensitive cell-line LNCaP, different methods were tried.


METHODS
After almost one year of continuous culture in RPMI-1640, containing a low concentration of androgens, the hormone sensitive cell-line LNCaP became hormone resistant and was named LNCaP-r.


RESULTS
We used the LNCaP/LNCaP-r model system in order to study methods for the parenteral treatment of prostate carcinoma with estrogens, to study the mechanism of action of estramustine, and to identify markers useful as predictive tests for prostate carcinoma.


CONCLUSIONS
A model system made up of the hormone sensitive prostate LNCaP cell-line and the hormone resistant LNCaP-r subline was developed and characterized. This system is, despite a number of limitations, easy to use as a first step to test different hypotheses that can be studied further in later clinical trials.
Pousette
A
A
Department of Clinical Chemistry, Karolinska Institute, Huddinge University Hospital, Sweden.
Carlström
K
K
Henriksson
P
P
Grande
M
M
Stege
R
R
D000728:Androgens / Q000494:pharmacology*; D018931:Antineoplastic Agents, Hormonal / Q000493:pharmacokinetics / Q000494:pharmacology; D014408:Biomarkers, Tumor; D002455:Cell Division / Q000187:drug effects; D004351:Drug Resistance; D004961:Estramustine / Q000493:pharmacokinetics / Q000494:pharmacology; D004967:Estrogens / Q000627:therapeutic use; D006728:Hormones / Q000494:pharmacology; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology* / Q000503:physiopathology*; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy; D012106:Research; D014407:Tumor Cells, Cultured
D000728:Androgens; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D004967:Estrogens; D006728:Hormones; D004961:Estramustine